Group items tagged

The Department of Health has published 'A Guide to Developing the Role of Consultant Pharmacists' in Northern Ireland on Thursday (22 June). The guidance provides direction on supporting a consistent approach to the introduction of senior clinical pharmacy roles within and across HSC organisations. The Chief Pharmaceutical Officer Professor Cathy Harrison said: "There is a recognised need for increased clinical pharmacy and medicines focussed leadership across our HSC." "Consultant Pharmacists have an essential role in healthcare as clinicians and as leaders who make a significant impact to medicines optimisation and clinical governance, providing a vital link between clinical practice and service development by generating and disseminating evidence to drive improvements in care. "I am delighted that this guidance has been published to take forward the strategic development and appointment of the consultant pharmacy workforce in both primary and secondary care and to enable pharmacy to be at the forefront of healthcare in NI".

Community pharmacy teams are urged to share their views relating to the new NHS Booking and Referral Standard (BaRS). "This will ensure that the tool supports the needs of pharmacy team members and their patients," said the Pharmaceutical Services Negotiating Committee (PSNC). BaRS is an interoperability standard for healthcare IT systems which should enable booking and referral information to be sent to or from care providers, such as community pharmacies, quickly, safely and in a format useful to clinicians. "The intentions are that the BaRS IT standard will eventually be available in all care settings. The way the standard could be used in pharmacies is currently being considered, including the potential for use for referrals from NHS 111 to community pharmacy." The BaRS team are conducting interviews (usually lasting 30-45 minutes) to hear more the current experiences and the future preferences regarding sending and receiving referral messages.

Representatives for prescribers across Scotland, politicians, academics and clinicians gathered to discuss the importance of environmental sustainability in healthcare during a Scottish Parliamentary reception held at Holyrood on Wednesday (13 December). Royal Pharmaceutical Society (RPS) informed the parliament that medicines account for around 25 per cent of carbon emissions across the NHS, while highlighting the various innovative ways to reduce these carbon emissions. The NHS in Scotland needs to implement effective environmentally sustainable approaches to healthcare in order to meet its ambition to achieve net zero, RPS pointed out. Laura Wilson, Director for Scotland at RPS, said: "It was fantastic to bring together pharmacists, parliamentarians and partners from across government and healthcare to highlight the huge opportunity which exists in healthcare to make our systems and processes more environmentally sustainable.

To curb the supply issue of HRT medicine, the government has taken a further action by issuing SSPs for Oestrogel, Ovestin cream, Lenzetto transdermal spray and Sandrena gel sachets - with appropriate alternatives. The move aims to allow community pharmacists to supply specified alternatives to the prescribed HRT products without needing to seek authorisation from the clinician who has prescribed the medicine. The regulator said that the availability of Premique Low Dose has impoved 'thanks to SSPs issued on 29 April to restrict dispensing for Oestrogel, Ovestin and Premique Low Dose to three months' supply'. "Since these measures were implemented, further deliveries of all three products have been made, with Premique Low Dose returning to good availability this week. The manufacturers of Oestrogel and Ovestin, as well as suppliers of alternative HRT products, are taking action to increase UK supply." It added, "SSPs restricting prescriptions to a maximum of three months' supply will also be issued for substitute products, as a precautionary measure to ensure the supply of those substitutes is maintained."

Community pharmacists in England have slammed the government's latest decision to reduce the number of people who get a free winter flu jab in the 2022-23 flu season, as concerns related to Covid-19 still exist. This follows a letter from the NHS England and NHS Improvement (NHSE&I) to clinicians, which stated that the flu vaccination service in 2022-23 will be offered to patient groups eligible in line with pre-pandemic recommendations. The eligibility was widened significantly after the pandemic struck in 2020 to help reduce the death toll from the Covid-19. With the change in place people aged 50-64 and schoolchildren aged 11-15 will not be eligible to receive the free jabs on the NHS next winter, pushing millions of people to pay for their jabs privately. It further recommended that vaccination for frontline healthcare workers and social care workers should be provided by employers as part of the organisation's policy to prevent the transmission of infection.

The Department of Health and Social Care (DHSC) has issued a medicine supply notification for antibiotics for the treatment of Group A Strep. "Supplies of antibiotics for the treatment of Group A Strep have seen a surge in demand and may be temporarily in limited supply at certain wholesalers and pharmacies," said DHSC. "Supplies are available with manufacturers, and deliveries into wholesalers and pharmacies are being expedited and are expected in the coming days." If the formulation of antibiotic prescribed is unavailable, DHSC has asked clinicians and local pharmacy teams to consider prescribing an alternative form or strength of the antibiotic where appropriate, ensuring the patient is not intolerant to any of the excipients in the alternative and is counselled on the appropriate dose (and volume) required.

PBR Staff Writer Published 21 March 2014 Novartis has launched the Lucentis (ranibizumab) pre-filled syringe (PFS) in Germany and plans to introduce the product in other markets throughout 2014. In October 2013, the company has received approval from the European authorities for Lucentis PFS, which is a new way of administering Lucentis that is specifically designed for intraocular injection to enhance patient safety and convenience for the treating clinician.

MIPS 2019 performance year is about to end. Only a little time is left until eligible clinicians can report for MIPS healthcare. MIPS put forwards the opportunity to get incentives and bonuses aside from the regular payment model.

It is about accuracy of data for each performance category that matters the most in MIPS. As a MIPS Qualified Registry for the fourth time in a row is a living proof of our past performances and current status. In this article, we got a chance to reflect on a few MIPS data essentials; and thought they would be useful for clinicians before the submission window closes for good.

Small Medical Practices! P3Care has been doing well as MIPS Qualified Registry for four years now. During this time, we come up with many little tricks to achieve a minimum performance threshold to be safe from the penalty. Read the article below to know how small practices can avoid the negative payment adjustment in MIPS 2019 reporting.

As a medical billing service, it is our primary duty to look after the revenue cycle management process of physicians on board. We are on a mission to narrate billing obligations in a fashion that is fast and in the direct interest of clinicians. Some of our clients have recorded their detailed feedback on Clutch

Physician enrollment and credentialing services are highly specific and difficult to execute. This process helps in hiring new doctors with verified data and credentials, ready to earn your trust as a reliable and trustworthy physician or specialty-specific clinician. Some medical billing companies also provide physician enrollment and credentialing services. 

Under MIPS QPP (Quality Payment Program), physicians report clinical data to CMS. They reward clinicians upon their contribution to make the current healthcare system an empowered one, incorporating technology and interoperability for patients' convenience.

We are dealing with a public health emergency, and CMS has proactively come forward to facilitate clinicians in Quality Payment Program (QPP). This year, the final rule for QPP MIPS data submission required some flexibility to accommodate the pressure.

Improvement activities (IA) - MIPS 2020 submission is incomplete without it - is easy to submit with the right MIPS consulting firm. Find out more about it.

Improvement activities (IA) - MIPS 2020 submission is incomplete without it - is easy to submit with the right MIPS consulting firm. Find out more about it.

Before implementing any EHR, EMR, or PM, clinicians must ask the right questions to see if the system adds value to their workflow or not. We have a list, read more.

CMS (Centers for Medicare and Medicaid Services) launched an alternative payment model - Primary Car. In this program, eligible clinicians can submit quality measures including for Advance Care Plan at the end of the performance year.

Clinicians concerning MIPS in 2020 face serious penalty consequences for not reporting MIPS 2020. They won't be able to get away with it if they don't participate resulting in a 9% deduction from their yearly Medicare payments.

However, with a much-improved situation now, the government encourages private practices and clinics to resume their normal operations. They are to continue with their postponed non-emergency treatments and carry out in-person patient visits as we speak.

America should adopt smarter ways to counter COVID-19 as it reopens for patients and clinicians. In the meanwhile, CMS has come up with a guide for patients and beneficiaries as they decide to visit providers for in-person care.

COVID emergency relief funds restrict medical billing services from sending surprise bills to patients on behalf of clinicians. Does this mean surprise billing is about to end?